Connect to other sites within the UBM Medica Network
Factors Used for Prognosis in Advanced Cervical Cancer
A new study yielded nomograms for the assessment of locally advanced cervical cancer, with prognostic factors including histology, performance status, and others.
Protecting Ovary Function During Breast Cancer Chemotherapy
The risk of early, sudden-onset menopause in women treated for early-stage breast cancer can be reduced with goserelin, a gonadotropin-releasing hormone agonist.
Fewer Lung Cancer Patients Eligible for Screening
A retrospective analysis suggested that a declining proportion of patients with lung cancer would meet the criteria for undergoing low-dose CT screening.
Patient Factors Linked With Ibrutinib Discontinuation
Researchers have identified patient factors linked with the discontinuation of ibrutinib therapy for reasons other than disease progression.
Ipilimumab Doubled 5-Year Survival in Advanced Melanoma
Advanced melanoma patients who received front-line ipilimumab/dacarbazine had double the 5-year survival rate compared with those on dacarbazine alone.
First-Line Option Clear in Sequencing of HER2-Positive Breast Cancer Treatments
As more treatment options become available for metastatic HER2-positive breast cancer, some questions regarding the optimal sequencing of therapies remain.
Exposure to In Utero Chemotherapy Did Not Affect Children’s Development, Behavior
In this video we discuss two poster presentations on childhood development and behavior after in utero exposure to chemotherapy for maternal cancer in pregnancy.
Breast Cancer Not Overdiagnosed by Mammography
The idea that breast cancer is overdiagnosed is being perpetuated in an effort to reduce access to breast cancer screening, according to a presentation at MBCC.
Lung-RADS Reduces False Positives, Sensitivity of Lung Screening
A classification system known as Lung-RADS reduced false positive rates but also decreased the sensitivity of low-dose CT screening compared with NLST standards.
Maintenance Sunitinib Improved PFS in Extensive-Stage SCLC
In a phase II study, the use of maintenance sunitinib improved progression-free survival among patients with untreated extensive-stage small-cell lung cancer.
By clicking Accept, you agree to become a member of the UBM Medica Community.